Total intravenous anaesthesia (TIVA) can reduce the risk of postoperative nausea and vomiting (PONV) almost as much as a single antiemetic. This study compared TIVA (using propofol and remifentanil) with prophylactic palonosetron (a 5hydroxytryptamine type 3 receptor antagonist) combined with inhalation anaesthesia using sevoflurane in 50% nitrous oxide, for the prevention of PONV. Patients were randomly assigned to one of two prophylactic interventions: (i) palonosetron 0.075 mg, intravenously before induction of inhalation anaesthesia (palonosetron group); and (ii) TIVA (propofol target blood concentration 2.5 -6.0 µg/ml; remifentanil target blood concentration 2.5 -6.0 ng/ml; TIVA group). Nausea/vomiting occurrence and severity were monitored immediately after the end of surgery for 24 h. The incidence of PONV was around 50% in both groups and the severity of nausea was similar in both groups. Prophylactic palonosetron with inhalational anaesthesia using sevoflurane in 50% nitrous oxide reduced the incidence of PONV after gynaecological laparoscopic surgery almost as much as TIVA using propofol and remifentanil.
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Introduction
Postoperative nausea and vomiting (PONV) is a highly undesirable complication that arises following surgery and anaesthesia. 1 Significant or uncontrolled PONV can lead to adverse consequences including patient dissatisfaction, unanticipated hospital admission, and delayed recovery and return to work. 2 Persistent retching or vomiting following surgery can put tension on suture lines, cause more serious postsurgical complications (such as wound dehiscence and surgical site bleeding) and place the patient at increased risk of pulmonary aspiration and dehydration. 3 -5 Although the incidence of PONV can vary (10 -79%), 6 it is consistently ranked by patients as one of the most distressing effects of surgery and anaesthesia. 7 Thus, it is very important for anaesthesiologists to avoid and control PONV.
The management of PONV has been advanced by the development of 5hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists, which inhibit the stimulatory effects of serotonin on afferent vagal pathways and the chemoreceptor trigger zone. 8, 9 Palonosetron is a new, potent, selective 5-HT 3 receptor antagonist that has a strong receptor binding affinity and a long elimination half-life, and, therefore, a long duration of efficacy. 10, 11 In a previous study that evaluated the efficacy of palonosetron compared with ondansetron in preventing PONV, it was reported that palonosetron 0.075 mg produced a lower incidence of PONV compared with ondansetron 8 mg in patients undergoing gynaecological laparoscopic surgery. 12 It has been demonstrated that total intravenous anaesthesia (TIVA) can reduce PONV risk almost as much as a single antiemetic, including ondansetron, in highrisk patients. 13 There have been no studies comparing TIVA (using propofol and remifentanil) with prophylactic palonosetron (prior to inhalation anaesthesia with sevoflurane) for the prevention of PONV. Thus, the present randomized, controlled study evaluated the efficacy of TIVA, using propofol and remifentanil, compared with prophylactic palonosetron prior to inhalation anaesthesia using sevoflurane, in patients undergoing gynaecological laparoscopic surgery.
Patients and methods

STUDY POPULATION
Consecutive patients aged ≥ 20 years, with American Society of Anesthesiologists physical classification status 1 or 2, 14 who were scheduled to undergo elective gynaecological laparoscopic surgery of ≥ 1 h duration at Incheon St Mary's Hospital, Incheon, Republic of Korea, between January and March 2011 were enrolled into the study.
Patients were excluded from the study if they had received antiemetics, steroids, or psychoactive medications within 24 h of study initiation. Patients with vomiting or retching in the 24 h preceding surgery, patients who had received cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry, and patients with ongoing vomiting from gastrointestinal disease were also excluded.
Study approval was obtained from the Institutional Review Board of Incheon St Mary's Hospital, and all patients provided written informed consent before enrolment.
STUDY DESIGN AND TREATMENT
Patients were randomly assigned to one of two prophylactic interventions, by computergenerated random numbers, as follows: (i) palonosetron before induction of SK Park, EJ Cho Palonosetron versus TIVA in preventing PONV anaesthesia using sevoflurane in 50% nitrous oxide (palonosetron group); and (ii) TIVA using propofol and remifentanil (TIVA group).
No patient received preanaesthetic medication. In the palonosetron group, a single dose of palonosetron (0.075 mg) was administered intravenously (i.v.) immediately before the induction of anaesthesia; anaesthesia was induced with propofol 2 mg/kg i.v. and maintained with 50% nitrous oxide in oxygen and 1 -4% sevoflurane. In the TIVA group, anaesthesia was induced and maintained with propofol (target blood concentration 2.5 -6.0 µg/ml) and remifentanil (target blood concentration 2.5 -6.0 ng/ml) using a target-controlled infusion device (Orchestra ® Base Primea ® ; Fresenius Vial, Brézins, France).
For all patients, tracheal intubation was facilitated with rocuronium 0.6 mg/kg i.v. and, at the completion of surgery, patients received pyridostigmine 0.2 mg/kg i.v. and glycopyrrolate 0.008 mg/kg i.v. for the reversal of neuromuscular blockade. For postoperative pain control, a patientcontrolled anaesthesia device was used, set to deliver a background infusion of fentanyl 20 µg/h, with a 5 µg i.v. bolus, and a lockout time of 15 min.
STUDY ASSESSMENTS
The occurrence of nausea and vomiting, the severity of nausea according to a visual analogue scale (VAS score: 0, no nausea; 10, worst nausea) and rescue antiemetic drug use were monitored immediately after the end of surgery and at 0 -2 h, 2 -6 h and 6 -24 h postsurgery. Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit, whereas an episode of vomiting was defined as vomiting (forceful expulsion of gastric contents from the mouth) or retching (laboured, spasmodic, rhythmic contractions of the respiratory muscles without expulsion of gastric contents). 4 Metoclopramide (10 mg, i.v.) was permitted as a rescue antiemetic when ≥ 2 episodes of PONV occurred or when the VAS score was > 5 and the patient requested treatment.
If metoclopramide was ineffective, ondansetron (4 mg, i.v.) was permitted.
Details of any adverse events (including headaches, dizziness, constipation and myalgia) were recorded and patients were also asked to rate their overall satisfaction on a 3-point scale (satisfied, neutral, and dissatisfied) 24 h after completion of surgery.
The primary outcome measure was the incidence of nausea and vomiting during the first 24 h after anaesthesia. Secondary outcomes were the severity of nausea, the need for rescue medication, patient satisfaction, and the incidence of adverse events.
STATISTICAL ANALYSES
The sample size was calculated by a power analysis while designing the study. Allowing an α error of 5% and a β error of 20%, it was estimated that a minimum of 49 patients per group would be required to show a 30% difference in the incidence of PONV. 15, 16 All statistical analyses were performed using the SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A Student's t-test was used to compare the intergroup differences and the χ 2 -test or Fisher's exact test were used to compare categorical variables. P-values were corrected by the Bonferroni method and a difference was regarded as statistically significant at a P-value < 0.05.
Results
One hundred patients were recruited (50 per SK Park, EJ Cho Palonosetron versus TIVA in preventing PONV group), all of whom completed the study. The patient characteristics, risk factors and operative data were not significantly different between the two groups ( Table 1) .
The incidence of PONV was similar in the palonosetron and TIVA groups during the 0 -24-h time interval (48.0% versus 50.0%, respectively; Table 2 ). There were no significant differences between the two groups in terms of the incidence of PONV at each time interval. The severity of nausea (VAS) and the need for rescue antiemetics ( Table 2) , and the incidence of adverse events and patient satisfaction ratings (Table 3) , were not significantly different between the two groups.
Discussion
A substantial percentage of patients continue to have PONV despite the widespread use of different kinds of interventions and prophylactic antiemetics, including 5-HT 3 receptor antagonists, 17 for the following reasons: a lack of understanding of PONV mechanisms; difficulties in estimating the individual risk; and the variability of the dose-response relationships for current interventions. 18 Of note, oesophageal rupture, subcutaneous emphysema and bilateral pneumothoraces have been associated with PONV. 19, 20 Palonosetron, a second-generation 5-HT 3 antagonist, has unique structural, pharmacological and clinical properties that distinguish it from other 5-HT 3 antagonists. 2 In a previous study of patients undergoing gynaecological laparoscopic surgery, palonosetron 0.075 mg i.v. significantly reduced the incidence of PONV compared with ondansetron 8 mg i.v. 12 Total intravenous anaesthesia with remifentanil and propofol is a useful and popular anaesthetic technique, effectively controlling responses to tracheal intubation and surgical stimulation and allowing for rapid emergence from anaesthesia. 21, 22 Sevoflurane is also widely used, providing both rapid anaesthetic induction and emergence, and is suitable for inhalation induction because of the lack of pungency. 23 Inhaled anaesthetics are a known cause of PONV 24 and it has been stated that propofolbased TIVA is as effective as a single antiemetic drug not including palonosetron. 13 The action of TIVA seems related to the direct reduction of 5-HT 3 levels in the area postrema, and subhypnotic doses of propofol are effective in reducing the incidence of PONV. 25, 26 It is possible that, compared with inhaled anaesthetics, the improved incidence of PONV after propofol administration is offset when opioids, including remifentanil, are added. 27 Some authors have, however, reported that propofol-remifentanil has a statistically lower incidence of PONV compared with sevoflurane-nitrous oxide. 28 Thus, the present study investigated whether SK Park, EJ Cho Palonosetron versus TIVA in preventing PONV or not palonosetron was better than TIVA in reducing PONV, despite the presence of inhaled anaesthetics. Based on a study showing that the use of propofol for anaesthesia induction, followed by a nonpropofol maintenance technique, does not result in PONV reduction, 29 in the present study, propofol was used for the induction of anaesthesia in the palonosetron group.
Palonosetron
The hypothesis for the present study was that sevoflurane and palonosetron would be more effective at preventing PONV compared with TIVA. However, in patients undergoing gynaecological laparoscopic surgery, no significant reduction in PONV was demonstrated in the palonosetron group compared with the TIVA group in the early and late postoperative periods. In agreement with these results, a previous study that compared two commonly used prophylactic strategies, sevoflurane combined with dolasetron and propofol-based TIVA, demonstrated similar efficacy with both regimens in the early postoperative period. 18 Paech et al. 30 found postdischarge nausea to be more common after inhalation anaesthesia plus dolasetron when compared with propofol-based TIVA; it is of note that, as in the present study, the authors included nitrous oxide as part of the inhalation anaesthesia. The analysis by Apfel et al. 13 reported that substituting nitrogen for nitrous oxide reduced the risk of PONV by 12%. It could be suggested that, in spite of the presence of nitrous oxide, the trend toward a lower incidence of PONV in the palonosetron group in the early and late postoperative periods in the present study is encouraging, even though no statistically significant difference was detected.
The incidence of PONV may be associated with many factors including age, gender, history of motion sickness or PONV, smoking status, type and duration of surgery and anaesthesia. 4, 31 These factors were wellbalanced between the two treatment groups in the present study. It was previously reported that late PONV (2 -24 h postsurgery) has different risk factors compared with early PONV; predictors of late PONV were early PONV and postoperative opioid use, and late PONV is more common 24 These factors were also well-balanced in the two groups in the present study.
Patients in the present study were still at a high risk for PONV after prophylactic intervention with palonosetron or TIVA (48.0% and 50.0%, respectively, during the 0 -24 h postoperative time interval), suggesting that patients at moderate or high risk for PONV should receive multimodal prophylaxis. 30 Because TIVA reduces the predicted rate of PONV in the early postoperative period only, a long-acting antiemetic drug might be necessary. 18 In a factorial trial of six interventions for the prevention of PONV, a 45% relative reduction in the risk of PONV was expected when TIVA was combined with one antiemetic in moderate-to high-risk patients; 13 however, this was only an 11 -15% additional absolute risk reduction compared with TIVA alone and would not justify the expense and risk of such prophylaxis. Thus, multimodal interventions (especially TIVA-palonosetron) should generally be reserved for patients at high risk for PONV or in whom PONV is dangerous. Careful studies are needed to identify the safety and cost effectiveness of this approach.
At present, propofol-remifentanil TIVA is generally more expensive than inhalational anaesthesia using sevoflurane-nitrous oxide. 32 Propofol-remifentanil TIVA might result in more postoperative pain because of the quick offset of the analgesic action, necessitating more analgesics and additional cost. Palonosetron is, however, more expensive than other 5-HT 3 antagonists and it would, therefore, be somewhat difficult to justify its cost effectiveness.
There were several limitations to the present study. When performing the power analysis, the expected incidence of PONV was estimated using patients who did not undergo identical types of surgery. Also, the baseline incidence of PONV was not evaluated by including a placebo group, because it was considered unethical to withhold prophylactic interventions in patients at high risk of PONV.
In conclusion, the present study demonstrated that prophylactic palonosetron administered intravenously immediately before induction anaesthesia using sevoflurane-nitrous oxide resulted in a similar reduction in PONV compared with propofol-remifentanil TIVA.
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